Phase 2 Study to Evaluation the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome

Inclusion Criteria: * Corneal staining score of ≥5 in either eye by the National Eye Institute/Industry Workshop guidelines * Schirmer test score (without anesthesia) \< 7 mm/5 min in either eye * Willing to use no topical ocular treatments, other than REFRESH TEARS® for the duration of the trial Exclusion Criteria: * Intraocular surgery within 3months * Persistent intraocular inflammation or infection * Corneal transplantation or neurotrophic keratitis * Stevens-Johnson Syndrome * Ocular herpes simplex virus infection * Concomitant use of contact lenses or use within 3months * Silicone lacrimal punctal occlusion or cauterization of the punctum within 3months * Vision correction surgery without DES within 12months * Unstable use of methotrexate or Disease-modifying drugs